Radionuclide Therapy

Promising New Treatment for Men with Metastatic Prostate Cancer Using Lutetium-177 PSMA

Prostate cancer is the fourth most common cancer affecting Malaysian men, with rates expected to escalate in the coming years, but a new treatment for prostate cancer that has spread to other parts of the body (metastatic) is showing promise that might lead to reduction in tumour burden without severe side effects, even in men who previously have received many other lines of treatment including chemotherapy, radiotherapy and hormonal therapy.

Prostatespecific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionizing the way consultants image and treat men with prostate cancer. New small molecular peptides with highbinding affinity for the PSMA receptor have allowed high quality, highly specific PET/CT imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer.

This targeted therapy for advanced prostate cancer has, to date, predominantly used Lutetium- 177 (177Lu) labeled PSMA peptides. Early clinical studies evaluating the safety and efficacy of 177Lu-PSMA therapy have demonstrated promising results with a significant proportion of men with advanced metastatic castrate resistant prostate cancer, who have already failed other therapies, responding clinically to 177Lu-PSMA.

177Lu-PSMA is a treatment that is increasingly being used for people with advanced castrate resistant prostate cancer in Europe and other parts of the world since 2015. This therapy aims to reduce the size of the tumor and halt them from multiplying, as well as ease the symptoms that patients may get with these tumors. Multiple clinical trials are currently being conducted worldwide to evaluate the possible therapeutic role of 177Lu in other malignancies such as breast and kidney cancers.

“Beacon Hospital is leading the way by being the first hospital in Malaysia and the ASEAN region, with a clinical trial for this new treatment for advanced castrate resistant prostate cancer.

“Targeted radionuclide therapies such as 177Lu-PSMA is promising to be a viable therapeutic option in men with metastatic prostate cancer and we at Beacon, are delighted to be the first in ASEAN to have this procedure done here at Beacon Hospital today.

Prostate cancer is treatable but its management can be complex. Individuals diagnosed with prostate cancer should consult both the urologist and the oncologist for various treatment options.

Search For Consultant